A distinctive trait of our study is the use of the recent classification of tumors according to WHO 2021, which excludes IDH-1 mutant patients from GBM and categorizes them as grade 4 astrocytomas. The gene discussed is IDH1; the disease is astrocytoma (excluding glioblastoma).